Fig. 6: Niclosamide inhibits polycystic kidney disease in a mouse model for ADPKD.
From: Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo
a, b Representative images of kidneys from non-induced (Pkd1+/+) (n = 4 animals) and induced (Pkd1−/−) mice, untreated (n = 5 animals) or treated with niclosamide (n = 8 animals). Scale bar 5000 µm. Tubule-specific deletion of Pkd1 (Pkd1−/−) was induced at postnatal days 20–22. Thereafter, mice were either treated with standard diet or diet supplemented with 0.2% niclosamide (Niclo) for 10 weeks. Pkd1+/+ mice fed with standard diet served as control. Cyst formation in Pkd1−/− (#P = 0.003) was strongly inhibited by niclosamide treatment (§P = 0.005). c, d Proliferating cells identified in Pkd1+/+ and Pkd1−/− kidneys by the proliferation marker ki-67 (red). Proliferation was enhanced in Pkd1−/− kidneys (#P < 0.0001), but was significantly inhibited by niclosamide (§P < 0.0001). Number of ki-67 positive cells was normalized to the tissue area (n = 25 independent images from 5 animals each). Mean and error bars indicating ±SEM. #§One-way ANOVA and Tukey’s post-hoc test. Source data are provided as a Source Data file.
